{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:03:16Z","timestamp":1791475396392,"version":"4.3.4"},"reference-count":14,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Carfilzomib use has been extensively associated with cardiovascular toxicity; the risk with ixazomib, a novel oral proteasome inhibitor, is underreported and no large comparative analysis is available.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective cohort study utilizing the TriNetX platform to compare toxicity outcomes among multiple myeloma patients who received lenalidomide, dexamethasone, and ixazomib (IRd) or carfilzomib (KRd).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After propensity\u2010score\u2010matching 478 patients from each cohort, the onset of new heart failure (HR 0.25; <jats:italic>p\u00a0<\/jats:italic>&lt;\u00a00.001) and arrhythmias (HR 0.57; <jats:italic>p<\/jats:italic> = 0.014) at 6\u00a0months were significantly lower with IRd while overall survival at 3\u00a0years was similar (<jats:italic>p<\/jats:italic> = 0.50).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>IRd is associated with a significantly lower risk of cardiac toxicities compared to KRd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jha2.70038","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T17:42:25Z","timestamp":1745862145000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd)"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1678-1345","authenticated-orcid":false,"given":"Benjamin J.","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Pharmacy Chao Family Comprehensive Cancer Center University of California Irvine Health  Orange California USA"},{"name":"Department of Clinical Pharmacy Practice School of Pharmacy &amp; Pharmaceutical Sciences University of California  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sayer","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Practice School of Pharmacy &amp; Pharmaceutical Sciences University of California  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Naqvi","sequence":"additional","affiliation":[{"name":"Division of Cardiology Department of Medicine University of California Irvine Health  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen T.","family":"Mai","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Practice School of Pharmacy &amp; Pharmaceutical Sciences University of California  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav M.","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Cardiology Department of Medicine University of California Irvine Health  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa X.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology Department of Medicine University of California Irvine Health  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-9322","authenticated-orcid":false,"given":"Aya F.","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Practice School of Pharmacy &amp; Pharmaceutical Sciences University of California  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"\u201cCancer Stat Facts: Myeloma \u201dNational Cancer Institute accessed April 21 2022 https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007522"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00882-y"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23933"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.2466"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008787"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71125-8"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14180"},{"key":"e_1_2_11_12_1","unstructured":"TriNetX \u201cPublication Guidelines \u201dTriNetX 2019 https:\/\/trinetx.com\/trinetx\u2010publicationguidelines\/."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.3854"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00432-4"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.23031"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T13:23:00Z","timestamp":1750684980000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/jha2.70038"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70038","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"2025-01-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70038"}}